Identification of key genes as potential diagnostic and therapeutic targets for comorbidity of myasthenia gravis and COVID-19.

Journal: Frontiers in neurology
Published Date: Feb 7, 2024

Abstract

INTRODUCTION: Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disorder. Coronavirus disease 2019 (COVID-19) has a significant impact on the health and quality of life of MG patients and may even trigger the onset of MG in some cases. With the worldwide development of the COVID-19 vaccination, several new-onset MG cases and exacerbations following the COVID-19 vaccines have been acknowledged. The potential link between myasthenia gravis (MG) and COVID-19 has prompted the need for further investigation into the underlying molecular mechanism.

Authors

  • Liyan Huang
    Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.
  • Yao Zuo
    Shandong University, Jinan, Shandong, China.
  • Hui Yang
    Department of Neurology, The Second Affiliated Hospital of Guizhou University of Chinese Medicine, Guiyang, China.
  • Xiaofang He
    Department of Pediatric Intensive Care Unit, Guizhou Provincial People's Hospital, Guiyang, China.
  • Lin Zhang
    Laboratory of Molecular Translational Medicine, Centre for Translational Medicine, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Clinical Research Center for Birth Defects of Sichuan Province, West China Second Hospital, Sichuan University, Chengdu, Sichuan, 610041, China. Electronic address: zhanglin@scu.edu.cn.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals